Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 6/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13813940 | 0.86 | CYP3A4 (0.63) | CYP3A4ALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL7412482 | 0.85 | CYP3A4 (0.50) | CYP3A4ALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL9191755 | 0.83 | CYP3A4 (0.49) | CYP3A4ALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL9191753 | 0.83 | CYP3A4 (0.49) | CYP3A4ALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL6540252 | 0.83 | ALDH1A1 (0.45) | CYP3A4ALDH1A1CYP2C9CYP2C19OPRM1 | |
| SCHEMBL24965070 | 0.83 | CYP3A4 (0.49) | CYP3A4ALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL6331086 | 0.82 | KMT2A (0.46) | CYP3A4ALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL5948337 | 0.82 | CYP3A4 (0.67) | CYP3A4ALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL6514301 | 0.80 | ALDH1A1 (0.65) | CYP3A4ALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL3135137 | 0.79 | CYP3A4 (0.55) | CYP3A4ALDH1A1CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-6706743-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2004-03-16 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-10-30 | — | — | US | disclosed |
| EP-1326861-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6566377-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | DAY ROBERT F (US) | 2002-05-02 | — | — | US | disclosed |
| WO-2002032897-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | CYP3A4 387/4885ALDH1A1 731/4885CYP2C9 420/4885 |
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | CYP3A4 381/4885ALDH1A1 843/4885CYP2C9 402/4885 |
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | CYP3A4 4197/4885ALDH1A1 188/4885CYP2C9 3959/4885 |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | ADRB3, ADRA1A, ADRB1 | CYP3A4 615/4885ALDH1A1 1413/4885CYP2C9 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.